EUVIMEDEUVIMED entdecken
Crossref

Engineered lipid nanoparticles enable therapeutic gene silencing of GTSE1 for the treatment of liver fibrosis

Michaela Jeong, Sumin Shin, Gyeongseok Lee, Yeji Lee, Seo Bhin Park, Jisoo Kang, Young-Sun Lee, Wonhyo Seo, Hyukjin Lee

Journal of Controlled Release · 2024-10 · 374 · 337-348

DOI: 10.1016/j.jconrel.2024.08.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-10. Verfasst von Michaela Jeong und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea. Hauptthemen laut MEDLINE: Liver Cirrhosis, Nanoparticles, Gene Silencing. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Center for Inter-University Research Facilities, Ministry of Food and Drug Safety, Korea Ministry of Science and ICT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver fibrosis is characterized by abnormal accumulation of extracellular matrix proteins, disrupting normal liver function. Despite its significant health impact, effective treatments remain limited. Here, we present the development of engineered lipid nanoparticles (LNPs) for targeted RNA therapeutic delivery in the liver. We investigated the therapeutic potential of modulating the G2 and S-phase expressed 1 (GTSE1) protein for treating liver fibrosis. Through screening, we identified P138Y LNP as a potent candidate with superior delivery efficiency and lower toxicity. Using these engineered LNPs, we successfully delivered siGTSE1 to hepatocytes, significantly reducing collagen accumulation and restoring liver function in a fibrosis animal model. Additionally, GTSE1 downregulation altered miRNA expression and upregulated hepatocyte nuclear factor 4 alpha (HNF4α). These findings suggest that therapeutic gene silencing of GTSE1 is a promising strategy for treating liver fibrosis by regenerating liver phenotypes and functions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisNanoparticlesGene SilencingAnimalsHumansMaleHepatocyte Nuclear Factor 4HepatocytesMice, Inbred C57BLLiverMicroRNAsRNA, Small InterferingLipidsLiposomes

Stichwörter der Autor:innen

GTSE1Gene silencingGene therapyLipid nanoparticlesLiver fibrosisTargeted delivery

Substanzen

Hepatocyte Nuclear Factor 4MicroRNAsRNA, Small InterferingLipidsLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea.
  • Department of Internal Medicine, Korea University Medical Center, Seoul 08308, Republic of Korea.
  • College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea. Electronic address: wonhyoseo@ewha.ac.kr.
  • College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea. Electronic address: hyukjin@ewha.ac.kr.

Förderung

  • National Center for Inter-University Research Facilities
  • Ministry of Food and Drug Safety
  • Korea Ministry of Science and ICT

Zitieren

APA

Jeong, M., Shin, S., Lee, G., Lee, Y., Park, S. B., Kang, J., Lee, Y. S., Seo, W., & Lee, H. (2024). Engineered lipid nanoparticles enable therapeutic gene silencing of GTSE1 for the treatment of liver fibrosis. Journal of Controlled Release, 374, 337-348. https://doi.org/10.1016/j.jconrel.2024.08.012

Vancouver

Jeong M, Shin S, Lee G, Lee Y, Park SB, Kang J, et al. Engineered lipid nanoparticles enable therapeutic gene silencing of GTSE1 for the treatment of liver fibrosis. Journal of Controlled Release. 2024;374:337-348. doi:10.1016/j.jconrel.2024.08.012

BibTeX
@article{Jeong2024,
  author = {Jeong, Michaela and Shin, Sumin and Lee, Gyeongseok and Lee, Yeji and Park, Seo Bhin and Kang, Jisoo and Lee, Young-Sun and Seo, Wonhyo and Lee, Hyukjin},
  title = {Engineered lipid nanoparticles enable therapeutic gene silencing of GTSE1 for the treatment of liver fibrosis},
  journal = {Journal of Controlled Release},
  year = {2024},
  volume = {374},
  pages = {337--348},
  doi = {10.1016/j.jconrel.2024.08.012}
}
Kostenlos starten →